Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

• Status: Completed
• Trial end date: 2003-03-13
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Glyburide; Repaglinide

Criteria

Inclusion Criteria:

• Newly diagnosed patients with type 2 diabetes currently treated with diet and exercise alone (HbA1c below 10%)

• Subjects with type 2 diabetes treated with sulphonylurea (HbA1c below 8.5%)

• Males or non-pregnant, non-lactating females

• Subjects should have normal renal function

Exclusion Criteria:

• Type 1 or other specific causes of diabetes

• Marked symptomatic diabetes

• Uncontrolled treated/untreated hypertension

• Known or suspected allergy to the trial products or related products